Healthpeak Properties raised its full-year earnings guidance after a second quarter marked by a 19.2% jump in senior housing same-store net operating income, even as its life science lab portfolio continued to lag, the healthcare REIT said in an Aug. 4 earnings release.
The S&P 500 healthcare REIT posted funds from operations as adjusted of 46 cents per share for the quarter. Total revenue for the first six months of 2026 reached $1.524 billion, and six-month net income came in at $262.9 million. Net income for the quarter alone was 8 cents per share.
Healthpeak owns a diversified healthcare real estate portfolio spanning outpatient medical buildings, life science lab space and senior housing communities nationwide, a mix the company has built in part through mergers, including its 2024 combination with Physicians Realty Trust. That diversification has become a selling point during a period when life science real estate nationally has struggled with an oversupply of lab space built during the pandemic-era biotech boom, even as an aging U.S. population has fueled steadier demand for senior housing and medical office space.
Senior housing offsets soft lab performance
The company’s three main property segments delivered sharply divergent results. Senior housing, which makes up 9.6% of Healthpeak’s portfolio, posted same-store NOI growth of 19.2% for the quarter β by far the strongest performance in the portfolio. Outpatient medical, the largest segment at 56.4% of the portfolio, grew same-store NOI 2.5%, with occupancy up 20 basis points sequentially to 90.7%.
The lab segment, 34% of the portfolio, was the weak spot: same-store NOI fell 3.2% even as occupancy improved 80 basis points sequentially to 78.5%, a gain of 140 basis points since the end of 2025. Healthpeak’s release did not specify what drove the lab segment’s revenue decline despite the occupancy gain, a pattern that can reflect softer asking rents or expiring leases rolling to lower rates in a life-science market that has faced an extended leasing slowdown nationally. Total portfolio same-store NOI grew 1.8% for the quarter.
Guidance raised, big-ticket capital recycling continues
Healthpeak nudged its full-year 2026 guidance higher across the board: diluted earnings per share to $0.48β$0.52, FFO as adjusted to $1.73β$1.77 per share, and same-store cash NOI growth to a range of 0%β1.5%, up 75 basis points at the midpoint from its prior outlook.
The quarter’s results were shaped in part by a large capital-recycling transaction: Healthpeak’s joint venture with Brookfield generated $1.025 billion in proceeds from selling a 49% stake in an 86-property, 5.6-million-square-foot portfolio. The company also collected $400 million from the repayment of seller financing and closed $40 million in outpatient medical property dispositions, bringing year-to-date proceeds from those combined transactions to $1.75 billion. Healthpeak maintains a monthly dividend of $0.10167 per share, or $1.22 annualized.
What it means
The 19.2% senior housing same-store NOI growth and the guidance increase are figures Healthpeak reported directly and are verified facts from the company’s own release. The lab segment’s NOI decline is also company-reported, though the release offers no explanation for it, and readers should treat any inference about the cause β softer life-science leasing demand nationally versus company-specific issues β as analysis rather than a confirmed fact. The scale of the Brookfield joint-venture sale and other dispositions shows Healthpeak continuing to actively recycle capital out of larger holdings, a strategy that has also shown up in smaller, market-specific deals such as the REIT’s $54 million purchase of a St. Augustine, Florida senior living community in late July.
What to watch: whether lab occupancy gains eventually translate into positive same-store NOI growth, and whether senior housing’s outsized growth rate β nearly eight times the outpatient medical segment’s pace β proves sustainable as it becomes a larger share of Healthpeak’s overall portfolio.
